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ABSTRACT 
Introduction: Chronic limb threatening ischaemia (CLTI) is a growing global health problem. The 
UK NIHR HTA-funded BASIL trial is still the only randomised controlled trial to have compared a 
bypass surgery first with a plain balloon angioplasty (PBA) first strategy for the management of 
CLTI.  In patients who were likely to survive for 2 years and had a suitable vein, primary bypass 
(PB) was associated with better clinical outcomes. Furthermore, PBA was associated with a high 
technical and clinical failure rate and many went on to have secondary bypass (SB). 
 
Aim: To compare clinical outcomes following PB and SB in the BASIL trial. 
 
Methods: Demographic, procedural and outcome data were obtained from the BASIL case report 
forms. Outcomes were amputation free survival (AFS), limb salvage (LS), overall survival (OS), and 
freedom from revascularisation (FFR). The SB cohort comprises patients whose first trial 
intervention was PBA and subsequently underwent bypass during follow-up. The PB cohort 
comprises those patients whose first trial intervention was bypass. 
 
Results: The 190 PB and 49 SB patients were well matched except that the SB patients were more 
likely to be current smokers. At a median of 7 years, PB was associated with better AFS (PB 60% vs 
SB 40%; HR=1.58, p=0.04), LS (PB 85% vs SB 73%, p=0.06), and OS (PB 68% vs 51%, p=0.06).  
FFR was equivalent (PB 53% vs 53%, p=0.3).  
 
Conclusion: In the BASIL trial, clinical outcomes following PB were significantly better than in 
patients undergoing SB after failed PBA.  Prior to treating patients with CLTI with primary PBA, 
clinicians should consider that if this should fail, the outcome of attempted subsequent bypass is 
likely to be significantly worse than if PB were attempted.  
INTRODUCTION 
Although chronic limb threatening ischaemia (CLTI) is a growing global health problem 1,2, the 
evidence underpinning the choice of revascularisation strategy remains poor. The UK NIHR HTA-
funded Bypass versus Angioplasty for Severe Ischaemia of the Limb (BASIL) trial remains the only 
randomised controlled trial (RCT) to have compared a ‘bypass surgery first’ with a ‘plain balloon 
angioplasty (PBA) first’ strategy for CLTI due to infra-inguinal disease 3.  An intention to treat 
analysis (ITT) of BASIL outcome data showed that, in patients who were likely to survive for at 
least 2 years and who had a suitable vein; primary bypass (PB) was led to better clinical outcomes 
than primary PBA. Furthermore, primary PBA was associated with a high technical and clinical 
failure rate such that many of the patients went on to have secondary bypass (SB).  Despite this 
‘level 1’ evidence in support of surgical bypass as the preferred revascularisation strategy for 
patients with a suitable vein, enthusiasm for an endovascular-first approach to most, perhaps even 
all, patients with CLTI continues to grow 4. As a result, vein bypass is increasingly being viewed as a 
secondary, salvage procedure to be performed when all endovascular revascularisation options have 
been exhausted 5,6. There are surprisingly few published reports of outcomes following SB for failed 
endovascular revascularisation. Furthermore, in the few studies that are available, patient numbers 
are often small, patients were not randomised, and patients with intermittent claudication and CLTI 
are often conflate 7,8,9.  This topic was briefly reported in the analysis by treatment received, only SB 
within 8 weeks of primary PTA were included and only AFS was reported but no further in depth 
analyses were performed10.  The aim of this study, therefore, was to compare clinical outcomes 
following PB and all SB after failed primary PBA in the BASIL trial. 
  
METHOD 
The BASIL trial methodology has been published previously3.  Ethical approval was obtained from 
the Multi-Centre Research Ethics Committee for Scotland.  Briefly, patients with CLTI due to infra-
inguinal disease were randomised to either a PB or primary PBA revascularisation strategy between 
1999 and 2004.  Patients were followed up until death or the censor date of 1 July 2007. This 
provided all surviving patients with a minimum of 3 years follow-up (median 51, range 0-92, 
months).    
BASIL trial case report forms (CRF) were interrogated to obtain demographic, procedural and 
outcome data including amputation free survival (AFS), limb salvage (LS), overall survival (OS), 
and freedom from re-intervention (FFR) defined as any further revascularisation of the index limb.  
The SB cohort comprises patients whose first trial intervention was PBA and who subsequently 
underwent SB (with any conduit) at any point during trial follow-up.  The PB cohort comprises those 
patients whose first trial intervention was PB with any conduit.  Time to event analyses are presented 
over a 7-year period using Kaplan-Meier plots.  Hazard ratios were used to detect statistically 
important differences in outcomes using 95% confidence intervals. Differences between the cohorts 
were compared using t-test, chi-squared and Wilcoxon Rank Sum tests according to distribution of 
data.  Statistical analysis was performed using SAS v 9.4. 
  
RESULTS 
There were 238 attempted primary PBA in the BASIL trial; of these, 69 patients went on to have a 
secondary intervention, 17 had a tertiary intervention and 7 had a fourth intervention.  25 (36.2%) of 
the secondary interventions were PBA; of these, 3 (12%) subsequently underwent SB.  The 
remaining 46 SB’s were performed after failed primary PBA. In BASIL, 190 patients underwent PB.  
The 190 PB and the 49 SB patients were well matched at the time of randomisation in terms of 
baseline demographics except that the SB patients were more likely to be current smokers (Table 1). 
Medical management was also similar (Table 2).  49% (24/49) of those who went on to have SB had 
a technically successful primary PBA.  Tissue loss was present in most patients in both groups (ulcer 
62% vs 69% p=0.3, gangrene 34% vs 29% p=0.5). The median time interval between primary PBA 
and SB was 0 months (range 0-20 months).  Of those who underwent PB, 9.5% (18/190) underwent 
secondary PTA, 94.4% (17/18) of these were for vein graft stenosis and 100% survived with their 
limb at the end of trial follow up. 
At a median of 7 years, PB was associated with significantly better AFS (PB 60% vs SB 40%; 
HR=1.58, 95% CI: 1.03-2.44, p=0.04).  Although LS and OS did not reach statistical significance 
there was a trend to better outcomes in the PB group (LS; PB 85% vs SB 73%; HR=1.86, 95% CI: 
0.97-3.58, p=0.06, and OS; PB 68% vs 51%; HR=1.57, 95% CI:0.97-2.54, p=0.06). FFR was the 
same in both groups (PB 53% vs 53%; HR=1.43, CI:0.74-2.74, p=0.3) except that, of course, by 
definition, those patients undergoing SB were all undergoing a re-intervention (Figures 2-5). 
Procedural data were available for all patients who underwent SB (Table 3).  All SB were deemed 
technically successful at the end of the procedure. Four (8%) SB were prosthetic compared with 22% 
(41/190) PB (p=0.03).  Absolute amputation rate to end of follow up was 15.3% vs 26.5% (p=0.06). 
The distal anastomosis was not statistically different between PB and SB with 68% (130/190) vs 
64% (31/49) being to the popliteal artery (p=0.4).  There was no significant difference between PB 
and SB in terms of 30-day morbidity and mortality (Table 4). 
  
DISCUSSION 
In the BASIL trial, 190 patients underwent PB and, of the 238 patients who underwent an attempt at 
primary PBA, 49 (21%) went on to require a SB at some point during the trial follow-up. The key 
finding of the present study is that PB was associated with statistically significant better AFS and a 
strong trend (p = 0.06) towards better LS and OS. We accept the SB group are a group of failures 
which suggests they are different to the PB group, the challenge for this analysis is to identify why?  
We also accept the BASIL trial was not powered to investigate this relationship, nevertheless it is an 
important relationship that is poorly understood.  The two cohorts were well matched in terms of 
baseline demographics and medical therapy at randomization, PB patients were more likely to be 
current smokers and have a history of TIA, however we note this group was observed to have better 
clinical outcomes. This suggests the observed differences are not related to the patient’s medical 
characteristics. Anatomical burden of disease is certainly influential in type of revascularization 
required and outcome of said intervention.  Bollinger analysis of these groups suggests there is no 
difference in burden or distribution of disease between these groups.  
The appropriateness of the observed trend in recent years towards an endovascular first strategy for 
most, perhaps even all, CLTI is now being challenged 11-13. However, although several groups have 
reported outcomes following PB and primary endovascular revascularisation, few have analysed the 
effect of failed endovascular intervention on the success of SB.  But, these reports, taken with the 
data from the BASIL trial presented here, indicate that primary endovascular intervention is not the 
“free shot” that it has so often been claimed to be. 
Although BASIL trial data are often said to be outdated and so no longer relevant to current practice, 
in reality, there is no evidence that that is the case14.  For example, Darling and colleagues recently 
studied 2869 patients undergoing lower limb revascularisation for CLTI and concluded that PB 
resulted in better outcomes in wound healing, FFR and OS; and that patients undergoing SB had 
higher rates of further intervention15. In another study, Jones and co-workers analysed 1154 CLTI 
patients undergoing SB and concluded these patients had worse MALE, FFR, OS and AFS16. 
Interestingly, although more BASIL patients in the PB group underwent synthetic bypass (PB 22% 
SB 8%), overall, the clinical results of PB were far superior to those observed after SB. In the UK, 
synthetic grafts are almost always reserved for those patients with no usable leg or arm vein 17-19.  As 
such, it could be argued patients undergoing prosthetic bypass should have been removed from this 
analysis. However, we decided to include them as a proportion CLTI patients requiring bypass will 
not have useable vein.  Approximately a third of the patients in each group underwent infra-popliteal 
bypass and so we can discount this as a cause of the differences observed between PB and SB. 
Going forward, it will be important to determine if drug coated balloons and drug eluting stents will 
increase the clinical success of primary endovascular intervention for CLTI.  The on-going UK 
NIHR HTA funded BASIL 2 and 3 trials 20,21, and US NIH funded BEST CLI trial22, will together 
recruit more than 3,500 CLTI patients undergoing PB and primary endovascular intervention and 
will address this and many other important question so informing evidence-based revascularisation 
(EBR). 
Conclusion  
 
In the BASIL trial, clinical outcomes following PB were significantly better than in patients 
undergoing SB after failed PBA.  Prior to treating patients with CLTI with primary PBA, clinicians 
should consider that if this should fail, the outcome of attempted subsequent bypass is likely to be 
significantly worse than if PB were attempted.  
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TABLES 
Table 1. Comparison of primary and secondary bypass patients in the BASIL trial 
  Primary Bypass Secondary Bypass p-value 
Number of Patients  190 49  
     
Age (years) Mean (SD) 72 (9.3) 73 (7.3) 0.4 
 Range 39 – 98 58 – 87   
Gender Male 127 (66%) 28 (57%) 0.2 
Limb Left 105 (55%) 27 (55%) 
1.0  Right 85 (45%) 22 (45%) 
ABPI Mean (SD) 0.5 (0.18) 0.48 (0.11) 0.5 
Smoker Never 30 (16%) 12 (24%) 
0.05  Ex 86 (45%) 13 (27%) 
 Current 74 (39%) 24 (49%) 
Diabetes No 113 (60%) 23 (47%) 
0.2  IDDM 31 (16%) 12 (24%) 
 NIDDM 46 (24%) 14 (29%) 
Hypercholesterolemia  No 45 (24%) 11 (22%) 
0.6 
 Yes, untreated 22 (11%) 3 (6%) 
 Yes, treated 66 (35%) 17 (35%) 
 No record of 
assessment 
57 (30%) 18 (37%) 
Hypertension No 77 (41%) 19 (39%) 
0.8  Yes, untreated 12 (6%) 2 (4%) 
 Yes, treated 101 (53%) 28 (57%) 
Mobility Independent 91 (48%) 22 (45%) 
0.8 
 Cane 79 (41%) 22 (45%) 
 Prosthesis 2 (1%) 1 (2%) 
 Wheelchair 13 (7%) 4 (8%) 
 Bed bound 5 (3%) 0 (-) 
Myocardial Infarction Yes 26 (14%) 8 (16%) 0.6 
Angina No 153 (81%) 44 (90%) 
0.2  Yes, on exercise 31 (16%) 3 (6%) 
 Yes, at rest 6 (3%) 2 (4%) 
TIA Yes 19 (10%) 1 (2%) 0.07 
Stroke Yes 25 (13%) 6 (12%) 0.9 
Rest Pain Yes 170 (89%) 45 (92%) 0.6 
Ulcer Yes 117 (62%) 34 (69%) 0.3 
Gangrene Yes 64 (34%) 14 (29%) 0.5 
Creatinine N 186 45  
 Mean (SD) 116 (79.4) 111 (62.0) 0.7 
 Range 50 – 702  40 – 452   
 
Abbreviations 
IDDM  - Insulin Dependent Diabetes Mellitus 
NIDDM - Non-Insulin Dependent Diabetes Mellitus 
TIA  - Transient Ischaemic Attack 
ABPI  - Ankle Brachial Pressure Index 
 
Table 2.  Medical management in patients undergoing primary and secondary bypass in BASIL 
  Primary Bypass Secondary Bypass p-value 
Number of Patients  190 49  
Antiplatelet None 52 (27%) 17 (35%) 
0.2 
 Single 111 (59%) 24 (49%) 
 Double 2 (1%) 1 (2%) 
 Antiplatelet + Other 15 (8%) 1 (2%) 
 Other 10 (5%) 6 (12%) 
Antihypertensive None 81 (43%) 18 (37%) 
0.3 
 One 53 (28%) 19 (39%) 
 Two 40 (21%) 6 (12%) 
 Two or more 16 (8%) 6 (12%) 
Statin None 123 (65%) 31 (63%) 
0.8  Yes 67 (35%) 18 (37%) 
Diabetes Treatment None 131 (69%) 25 (51%) 0.1 
 
Table 3. Frequencies of proximal and distal anastomosis location for primary and secondary bypass. 
  Primary Bypass 
Secondary 
Bypass p-value 
Number of Patients  190 49  
Distal Anastomosis 
Not Known 2 (1%) 0 (-) 
0.4 
AKPA 63 (33%) 10 (20%) 
BKPA 67 (35%) 21 (44%) 
PTA 17 (9%) 2 (4%) 
ATA 20 (11%) 9 (18%) 
PA 17 (9%) 6 (12%) 
DP 2 (1%) 0 (-) 
TPS 1 (0.5%) 1 (2%) 
DPP 1 (0.5%) 0 (-) 
Conduit Vein 149 (78%) 45 (92%) 0.03 Synthetic  41 (22%) 4 (8%) 
 
Abbreviations 
AKPA - Above Knee Popliteal Artery 
BKPA - Below Knee Popliteal Artery 
PTA - Posterior Tibial Artery  
ATA - Anterior Tibial Artery 
PA - Peroneal Artery 
DP - Dorsalis Pedis 
TPS - Tibial Peroneal Stem 
DPP - Dual Popliteal and Pedal 
  
Table 4: Mortality and morbidity (30 days) in patients undergoing primary and secondary bypass in 
BASIL 
 
 Primary 
Bypass 
Secondary 
Bypass p-value 
Number of Patients 190 49  
Angina 2 (1%) 0 (-) 0.5 
MI 8 (4) 2 (4) 1.0 
TIA 0 (-) 0 (-) - 
CVA 1 (0.5%) 1 (2%) 0.3 
Haematoma (no surgery) 8 (4%) 1 (2%) 0.5 
Haematoma (surgery) 3 (2%) 0 (-) 0.4 
LRTI 6 (3%) 1 (2%) 0.7 
UTI 9 (5%) 1 (2%) 0.4 
False Aneurysm (no surgery) 1 (0.5%) 0 (-) 0.6 
False Aneurysm (surgery) 0 (-) 0 (-) - 
30 Day Mortality 11 (6%) 4 (8%) 0.5 
30 Morbidity & Mortality 83 (44%) 19 (39%) 0.5 
MACE 17 (9%) 6 (12%) 0.5 
 
Abbreviations 
MI  –  Myocardial Infarction 
TIA - Transient Ischaemic Attack 
CVA - Cerebro-Vascular Accident 
LRTI - Lower Respiratory Tract Infection 
UTI - Urinary Tract Infection 
MACE - Major Adverse Cardiac Event 
 
Table 5. A comparison of Bollinger scores between primary and secondary bypass. 
 
SEGMENT STATS PB SB P-VALUE 
Profunda MEAN (SD) 2.4 (3.4) 2.5 (3.6) 0.828 
Proximal SFA MEAN (SD) 6.7 (5.6) 5.8 (5.3) 0.3 
Distal SFA MEAN (SD) 9.2 (5.4) 10.4 (5.0) 0.2 
Proximal POP MEAN (SD) 6.6 (5.7) 7.3 (6.3) 0.5 
Distal POP MEAN (SD) 3.7 (5.1) 3.7 (5.1) 1.0 
TPT MEAN (SD) 4.1 (5.8) 2.8 (5.0) 0.2 
Proximal PT MEAN (SD) 8.5 (7.0) 8.7 (7.0) 0.9 
Distal PT MEAN (SD) 9.7 (6.5) 9.2 (6.9) 0.7 
Proximal AT MEAN (SD) 6.9 (6.5) 8.5 (7.0) 0.2 
Distal AT MEAN (SD) 7.3 (6.9) 8.7 (7.0) 0.3 
Proximal PERO MEAN (SD) 4.8 (5.8) 4.2 (5.9) 0.6 
Distal PERO MEAN (SD) 5.5 (6.5) 2.2 (5.0) 0.005 
Total FP score MEAN (SD) 25.7 (9.9) 26.3 (9.0) 0.7 
Total IP score MEAN (SD) 45.3 (24.8) 46.3 (26.6) 0.8 
Total score MEAN (SD) 71.1 (26.4) 72.7 (26.6) 0.8 
Abbreviations 
 
SFA  –  Superficial Femoral Artery 
POP  - Popliteal Artery 
TPT - Tibio-Peroneal Trunk 
PT  –  Posterior Tibial Artery 
AT - Anterior Tibial Artery 
PERO - Peroneal Artery 
SD - Standard Deviation  
FIGURES 
 
Figure 1. Comparison of amputation free survival in patients undergoing primary and secondary 
bypass in the BASIL trial
 
Figure 2: Comparison of limb salvage in patients undergoing primary and secondary bypass in the 
BASIL trial 
 
  
Figure 3: Comparison of overall survival in patients undergoing primary and secondary bypass in the 
BASIL trial 
 
Figure 4: Comparison of freedom from re-intervention in patients undergoing primary and secondary 
bypass in the BASIL trial 
 
 
 
